Novakand Pharma AB (publ) (LARK) — Cash Flow-to-Debt Ratio
Novakand Pharma AB (publ) (LARK) has a Cash Flow-to-Debt Ratio of -1.32x as of December 2025, meaning its operating cash flow of Skr-1.64 Million could theoretically repay -1% of its total liabilities (Skr1.24 Million) in one year. Check total reinvestment intensity of Novakand Pharma AB (publ) to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Novakand Pharma AB (publ) Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Novakand Pharma AB (publ) across 14 annual periods. Also explore LARK asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Novakand Pharma AB (publ) (2012–2025)
Year-by-year debt coverage analysis for Novakand Pharma AB (publ). For market capitalisation and broader financial context, see Novakand Pharma AB (publ) (LARK) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -10.31x | Skr-12.78 Million | Skr1.24 Million | ▼ -48.1% |
| 2024 | -6.96x | Skr-29.95 Million | Skr4.30 Million | ▲ +5.3% |
| 2023 | -7.35x | Skr-30.56 Million | Skr4.16 Million | ▼ -169.1% |
| 2022 | -2.73x | Skr-16.67 Million | Skr6.10 Million | ▼ -198.1% |
| 2021 | 2.78x | Skr22.11 Million | Skr7.94 Million | ▲ +158.0% |
| 2020 | -4.80x | Skr-38.35 Million | Skr7.98 Million | ▼ -422.9% |
| 2019 | -0.92x | Skr-21.60 Million | Skr23.51 Million | ▼ -6018.6% |
| 2018 | 0.02x | Skr227.60K | Skr14.66 Million | ▲ +100.3% |
| 2017 | -5.86x | Skr-9.53 Million | Skr1.63 Million | ▲ +46.2% |
| 2016 | -10.88x | Skr-8.81 Million | Skr809.66K | ▼ -19.7% |
| 2015 | -9.09x | Skr-6.29 Million | Skr691.73K | ▼ -752.1% |
| 2014 | -1.07x | Skr-620.67K | Skr582.04K | ▲ +83.9% |
| 2013 | -6.64x | Skr-272.15K | Skr40.98K | ▼ -3426.4% |
| 2012 | 0.20x | Skr59.21K | Skr296.58K | — |